Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Savant Capital LLC

Savant Capital LLC decreased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 55.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,222 shares of the biopharmaceutical company’s stock after selling 7,706 shares during the quarter. Savant Capital LLC’s holdings in Intra-Cellular Therapies were worth $520,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. True Wealth Design LLC acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth about $32,000. GAMMA Investing LLC lifted its position in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth about $74,000. Wilmington Savings Fund Society FSB acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth about $97,000. Finally, Quarry LP lifted its position in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.2 %

Shares of Intra-Cellular Therapies stock opened at $127.82 on Monday. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.19. The business has a 50-day moving average price of $105.80 and a 200 day moving average price of $88.04. The firm has a market cap of $13.59 billion, a PE ratio of -146.92 and a beta of 0.72.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

ITCI has been the subject of a number of research reports. StockNews.com initiated coverage on Intra-Cellular Therapies in a research report on Sunday. They set a “hold” rating for the company. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and an average target price of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.